

2014 YEAR IN REVIEW



CANCER
RESEARCH
TECHNOLOGY

KEY INITIATIVES

FINANCIALS

£50M

CRT's cumulative return to CRUK surpassed this milestone in 2014

£28.8M

Industry funds leveraged by CRT to support CRUK projects over the past two years

MAJOR DEALS

Jan 2014
Collaboration between CRT, ICR and Nuevolution to screen potential cancer drugs

August 2014
CRUK, CRT and Astellas to conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer

September 2014
Inivata, a new spin-out arising from the CRUK Cambridge Institute at the University of Cambridge, raises £4m in funding round

October 2014
CRUK and LLR team up to boost blood cancer trials

November 2014
CRUK drug discovery investigators to be given access to AstraZeneca screening facilities



Co-funding scheme with Bayer launched



Joint CRUK-MEDI Alliance Laboratory established



Launch of Ximbio, an online portal for research reagents

PROJECT DEVELOPMENT

- Scientists visited
- Deals completed
- Patents filed
- New projects sourced
- = 10



EARLY DIAGNOSIS

PILOT PHASE

Following the successful completion of a pilot phase, three new companies join an alliance between Cancer Research UK, CRT and Abcodia to identify blood markets for early cancer diagnosis

DRUG DISCOVERY

aPKC PROJECT

CRT and Teva's collaboration yields successful outcome with novel aPKC protein inhibitor cancer drug discovery candidate. FORMA DUBs alliance successfully extended into second year

FUNDING INITIATIVES

5th

The number of investments by the CRT Pioneer Fund (CPF) increases to five, including an investment to develop lung cancer drugs at the CRUK Manchester Institute. BACIT joins CPF and commits £20m

CRT is dedicated to 'Advancing Discoveries to Beat Cancer'

OUR PIPELINE

Key progressions:



RG7813

Drug based on a Cancer Research UK discovery, progressed into a Phase 1 trial by Roche (March 2014)



GSK1070916A

The first trial to conclude under the Clinical Developments Partnerships (CDP) initiative (March 14)



IMA950

The first CDP project to complete a clinical trial and be taken forward by the company for further development (April 2014)



BTH1704

Cancer Research UK generated antibody taken into a Phase 1 trial in pancreatic cancer by Biothera (October 2014)

| AGENT/TARGET | DEVELOPMENT STAGE | | | | |
|--------------|-------------------|---------|----------|-----------|--------|
| | PRECLINICAL | PHASE I | PHASE II | PHASE III | MARKET |
| Temodal® | ●●●●● | ●●●●● | ●●●●● | ●●●●● | ●●●●● |
| Zytiga® | ●●●●● | ●●●●● | ●●●●● | ●●●●● | ●●●●● |
| Erivedge™ | ●●●●● | ●●●●● | ●●●●● | ●●●●● | ●●●●● |
| PARP | ●●●●● | ●●●●● | ●●●●● | ●●●●● | |
| TG4010 | ●●●●● | ●●●●● | ●●●●● | | |
| HSP90 | ●●●●● | ●●●●● | ●●●●● | | |
| SG 2000 | ●●●●● | ●●●●● | ●●●●● | | |
| Akt/PKB | ●●●●● | ●●●●● | ●●●●● | | |
| GSK1070916A | ●●●●● | ●●●●● | ●●●●● | | |
| IMA950 | ●●●●● | ●●●●● | ●●●●● | | |
| PI 3-kinase | ●●●●● | ●●●●● | ●●●●● | | |
| ONX-0801 | ●●●●● | ●●●●● | ●●●●● | | |
| AT 13148 | ●●●●● | ●●●●● | ●●●●● | | |
| AZD 0424 | ●●●●● | ●●●●● | ●●●●● | | |
| AZD 3965 | ●●●●● | ●●●●● | ●●●●● | | |
| DI-B4 | ●●●●● | ●●●●● | ●●●●● | | |
| RG7813 | ●●●●● | ●●●●● | ●●●●● | | |
| Undisclosed | ●●●●● | | | | |
| AZD2098 | ●●●●● | | | | |
| AST-VAC2 | ●●●●● | | | | |

● CRT PROJECT
● CDP PROJECT


As of Oct 2014

INDUSTRY INTERACTIONS



More than 150 face-to-face meetings held with leading pharma, biotech, tech transfer offices and investment funds at key industry events in 2014

OUR OFFICES



CRT Head Office
CRT-DL London
CRT-DL Cambridge

BUZZ GENERATED



61% increase in Twitter followers. Join the discussion @CRT_News

December 2014: CRT-DL London moved to the London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH

T: +44 (0)20 3469 6300
E: enquiries@cancertechnology.com

AND FINALLY



100+ cakes eaten by the CRT team during SU2C



26.2 miles our CSO Clive will be running in the 2015 London Marathon, in support of CRUK